Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : BridgeBio Pharma
Deal Size : $300.0 million
Deal Type : Demerger
BridgeBio launches another offshoot with $300M and early genetic disease programs
Details : GondolaBio will conduct R&D activities for early-stage clinical or preclinical programs across erythropoietic protoporphyria, alpha-1 antitrypsin deficiency and tuberous sclerosis complex.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 21, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : BridgeBio Pharma
Deal Size : $300.0 million
Deal Type : Demerger